TargetBeta
GCGR
glucagon receptor · also GGR · Glucagon receptor family
7 programs in company-led studies act on GCGR, from 7 companies: 4 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| UBT251 | The United Laboratories International | phase 3 | 1212 running | GIPR, GLP1R | a judged reading |
| retatrutiderule | Eli Lilly | phase 3 | 3311 running | GIPR, GLP1R | ChEMBL |
| survodutide | Boehringer Ingelheim | phase 3 | 3510 running | GLP1R | the company's pipeline |
| DR10624rule | Huadong Medicine | phase 3 | 64 running | GLP1R | the studies' text |
| AZD9550 | AstraZeneca | phase 2 | 75 running | GLP1R | a judged reading |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 54 running | GIPR, GLP1R | the company's pipeline |
| efinopegdutide | Johnson & Johnson | phase 2 | 150 running | GLP1R | a judged reading |
Conditions their studies are in
- Obesity, 6 programs
- Diabetes Mellitus, Type 2, 5 programs
- Non-alcoholic Fatty Liver Disease, 4 programs
- Fatty Liver, 3 programs
- Atherosclerosis, 1 program
- Diabetes Mellitus, 1 program
- Hypertriglyceridemia, 1 program
- Kidney Failure, Chronic, 1 program
- Liver Cirrhosis, 1 program
- Lymphoma, Follicular, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026retatrutide · Eli Lilly · phase 3 · NCT06662383
- Dec 2026UBT251 · The United Laboratories International · phase 3 · NCT07785934
- Dec 8, 2026survodutide · Boehringer Ingelheim · phase 3 · NCT07768813
- Jan 29, 2027AZD9550 · AstraZeneca · phase 2 · NCT06151964
- Mar 2027HRS-4729 · Jiangsu HengRui Medicine · phase 2 · NCT07690826
- Apr 2028DR10624 · Huadong Medicine · phase 3 · NCT07848880
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.